TME PHARMA NV (ALTME.PA) Stock Price, Quote, News and Overview
EPA:ALTME - Euronext Paris - Matif - NL0015000YE1 - Common Stock - Currency: EUR
ALTME.PA Quote, Performance and Key Statistics
EPA:ALTME (7/8/2025, 7:00:00 PM)
0.101
-0.01 (-6.48%)
The current stock price of ALTME.PA is 0.101 EUR. In the past month the price increased by 16.49%. In the past year, price decreased by -27.86%.
ALTME.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.74 | 290.04B | ||
| AMG.DE | AMGEN INC | 14.31 | 136.36B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.56 | 119.69B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 102.66B | ||
| 1VRTX.MI | VERTEX PHARMACEUTICALS INC | 1538.4 | 98.76B | ||
| ARGX.BR | ARGENX SE | 101.55 | 28.34B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.91B | ||
| IDP.DE | BIOGEN INC | 8.48 | 16.78B | ||
| 0QF.DE | MODERNA INC | N/A | 10.94B | ||
| 1MRNA.MI | MODERNA INC | N/A | 9.97B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.63B | ||
| YTSN.DE | KUROS BIOSCIENCES AG-REG | N/A | 1.11B |
Related stock screener links
About ALTME.PA
Company Profile
TME Pharma NV is a clinical-stage biopharmaceutical company, which focuses on therapeutics targeting the tumor microenvironment or TME. The company is headquartered in Berlin, Berlin and currently employs 13 full-time employees. The company went IPO on 2018-09-10. The firm specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. their clinical programs in glioblastoma and pancreatic cancer have delivered results and further development is planned.
Company Info
TME PHARMA NV
Max-Dohrn-Str. 8-10
Berlin BERLIN DE
Employees: 13
Phone: 49307262470
TME PHARMA NV / ALTME.PA FAQ
What is the stock price of TME PHARMA NV today?
The current stock price of ALTME.PA is 0.101 EUR. The price decreased by -6.48% in the last trading session.
What is the ticker symbol for TME PHARMA NV stock?
The exchange symbol of TME PHARMA NV is ALTME and it is listed on the Euronext Paris - Matif exchange.
On which exchange is ALTME.PA stock listed?
ALTME.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for TME PHARMA NV stock?
10 analysts have analysed ALTME.PA and the average price target is 0.36 EUR. This implies a price increase of 260.03% is expected in the next year compared to the current price of 0.101. Check the TME PHARMA NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TME PHARMA NV worth?
TME PHARMA NV (ALTME.PA) has a market capitalization of 9.51M EUR. This makes ALTME.PA a Nano Cap stock.
How many employees does TME PHARMA NV have?
TME PHARMA NV (ALTME.PA) currently has 13 employees.
What are the support and resistance levels for TME PHARMA NV (ALTME.PA) stock?
TME PHARMA NV (ALTME.PA) has a support level at 0.09 and a resistance level at 0.11. Check the full technical report for a detailed analysis of ALTME.PA support and resistance levels.
Is TME PHARMA NV (ALTME.PA) expected to grow?
The Revenue of TME PHARMA NV (ALTME.PA) is expected to decline by -25% in the next year. Check the estimates tab for more information on the ALTME.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TME PHARMA NV (ALTME.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALTME.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALTME.PA, evaluating the profitability, health, valuation and growth aspects
- TME PHARMA NV (ALTME.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TME PHARMA NV (ALTME.PA) Sales and EPS estimates to see what analysts future expectations are.
- TME PHARMA NV (ALTME.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TME PHARMA NV (ALTME.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- TME PHARMA NV (ALTME.PA) Stock Chart to make your own analysis
- TME PHARMA NV (ALTME.PA) Latest news and press-releases to stay up to date.
Does TME PHARMA NV (ALTME.PA) stock pay dividends?
ALTME.PA does not pay a dividend.
What is the Price/Earnings (PE) ratio of TME PHARMA NV (ALTME.PA)?
TME PHARMA NV (ALTME.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
ALTME.PA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ALTME.PA. When comparing the yearly performance of all stocks, ALTME.PA turns out to be only a medium performer in the overall market: it outperformed 53.39% of all stocks.
ALTME.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALTME.PA. ALTME.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALTME.PA Financial Highlights
Over the last trailing twelve months ALTME.PA reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS increased by 88.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -168% | ||
| ROE | -354.52% | ||
| Debt/Equity | 0 |
ALTME.PA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to ALTME.PA. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -64.91% and a revenue growth -25% for ALTME.PA